Loading...
You are here:  Home  >  Data Education  >  Big Data News, Articles, & Education  >  Big Data News  >  Current Article

Cytobank Brings the Big Data Revolution to Immunotherapy Clinical Research

By   /  November 7, 2016  /  No Comments

cyby Angela Guess

A recent press release states, “Cytobank launched its implementation of CITRUS, an algorithm that accelerates and automates biomarker discovery, on its leading cloud-based data analysis and management platform for collaborative single cell research. Biomarkers are used to measure and monitor patients in clinical trials and assist with the development of effective immunotherapies and other treatments for diseases including cancer. The high dimensional (HD) analysis resolution enabled by Cytobank’s platform empowers teams of researchers to collaboratively analyze cytometry data for an understanding of a patient’s response to an immunotherapy treatment at the single cell level. Single cell analysis resolves biological complexity by examining the immune system on a cell by cell basis. HD single cell analysis is growing rapidly due to the broader biological pathway understanding it enables and the recent availability of technologies including Mass Cytometry and Next Generation Sequencing.”

The release goes on, “Immunotherapy is one of the most promising current developments in cancer care, yet there is significant uncertainty regarding which combinations of therapies safely and effectively work for which patients. Cytobank brings clinical researchers the power of Big Data analytics and scalable on-demand, cloud-based computing to help them quickly answer complicated immunological data analysis questions. CITRUS in Cytobank helps researchers more quickly identify clinical biomarkers which can predict which patients will respond to which treatments. ‘With our Mass Cytometry studies and analysis, we often have the impression of assembling a railroad track right in front of the train, and incorporating CITRUS has helped us build the track out faster and further ahead than before. We can now do in two weeks what would otherwise take months of slicing populations into smaller groups to conduct the analysis,’ said Patrick Reeves, Ph.D., Team Leader, Vaccine & Immunotherapy Center, Massachusetts General Hospital.”

Read more at Marketwired.

Photo credit: Cytobank

You might also like...

Disrupting Metadata Management with Metadata Automation

Read More →
We use technologies such as cookies to understand how you use our site and to provide a better user experience. This includes personalizing content, using analytics and improving site operations. We may share your information about your use of our site with third parties in accordance with our Privacy Policy. You can change your cookie settings as described here at any time, but parts of our site may not function correctly without them. By continuing to use our site, you agree that we can save cookies on your device, unless you have disabled cookies.
I Accept